Cheah Phaik-Leng, Li Jing, Looi Lai-Meng, Teoh Kean-Hooi, Ong Diana Bee-Lan, Arends Mark J
Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Division of Pathology, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom.
PeerJ. 2018 Sep 11;6:e5530. doi: 10.7717/peerj.5530. eCollection 2018.
Except for a few studies with contradictory observations, information is lacking on the possibility of association between DNA mismatch repair (MMR) status and the presence of cancer stem cells in colorectal carcinoma (CRC), two important aspects in colorectal carcinogenesis.
Eighty (40 right-sided and 40 left-sided) formalin-fixed, paraffin-embedded primary CRC were immunohistochemically studied for CD133, a putative CRC stem cell marker, and MMR proteins MLH1, MSH2, MSH6 and PMS2. CD133 expression was semi-quantitated for proportion of tumor immunopositivity on a scale of 0-5 and staining intensity on a scale of 0-3 with a final score (units) being the product of proportion and intensity of tumor staining. The tumor was considered immunopositive only when the tumor demonstrated moderate to strong intensity of CD133 staining (a decision made after analysis of CD133 expression in normal colon). Deficient MMR (dMMR) was interpreted as unequivocal loss of tumor nuclear staining for any MMR protein despite immunoreactivity in the internal positive controls.
CD133 was expressed in 36 (90.0%) left-sided and 28 (70.0%) right-sided tumors ( < 0.05) and CD133 score was significantly higher in left- (mean ± SD = 9.6 ± 5.3 units) compared with right-sided tumors (mean ± SD = 6.8 ± 5.6 units) < 0.05). dMMR was noted in 14 (35%) right-sided and no (0%) left-sided CRC. When stratified according to MMR status, dMMR cases showed a lower frequency of CD133 expression (42.9%) and CD133 score (mean ± SD = 2.5 ± 3.6 units) compared with pMMR tumors on the right (frequency = 84.6%; mean score ± SD = 9.2 ± 5.0 units) as well as pMMR tumors on the left (frequency = 90.0%; mean score ± SD = 9.6 ± 5.3 units) ( < 0.05). Interestingly, frequencies of CD133 immunoreactivity and CD133 scores did not differ between pMMR CRC on the right versus the left ( > 0.05).
Proficient MMR correlated with high levels of CD133-marked putative cancer stem cells in both right- and left-sided tumors, whereas significantly lower levels of CD133-marked putative cancer stem cells were associated with deficient MMR status in colorectal carcinomas found on the right.
除了少数研究结果相互矛盾外,关于DNA错配修复(MMR)状态与结直肠癌(CRC)中癌症干细胞的存在之间是否存在关联,目前仍缺乏相关信息,而这两个方面在结直肠癌发生过程中都很重要。
对80例(40例右侧和40例左侧)福尔马林固定、石蜡包埋的原发性CRC进行免疫组织化学研究,检测假定的CRC干细胞标志物CD133以及MMR蛋白MLH1、MSH2、MSH6和PMS2。CD133表达通过肿瘤免疫阳性比例(0 - 5分)和染色强度(0 - 3分)进行半定量,最终得分(单位)为肿瘤染色比例与强度的乘积。仅当肿瘤显示CD133染色为中度至强强度时(在分析正常结肠中CD133表达后做出的决定),该肿瘤才被视为免疫阳性。错配修复缺陷(dMMR)被解释为尽管内部阳性对照有免疫反应性,但任何MMR蛋白的肿瘤细胞核染色明确缺失。
CD133在36例(90.0%)左侧肿瘤和28例(70.0%)右侧肿瘤中表达(P < 0.05),左侧肿瘤的CD133得分(均值±标准差 = 9.6 ± 5.3单位)显著高于右侧肿瘤(均值±标准差 = 6.8 ± 5.6单位)(P < 0.05)。在14例(35%)右侧CRC中发现dMMR,左侧CRC中未发现(0%)。根据MMR状态分层时,与右侧的错配修复功能正常(pMMR)肿瘤(频率 = 84.6%;平均得分±标准差 = 9.2 ± 5.0单位)以及左侧的pMMR肿瘤(频率 = 90.0%;平均得分±标准差 = 9.6 ± 5.3单位)相比,dMMR病例的CD133表达频率(42.9%)和CD133得分(均值±标准差 = 2.5 ± 3.6单位)较低(P < 0.05)。有趣的是,右侧与左侧的pMMR CRC之间,CD133免疫反应性频率和CD133得分没有差异(P > 0.05)。
在右侧和左侧肿瘤中,错配修复功能正常均与高水平的CD1标记假定癌症干细胞相关,而在右侧发现的结直肠癌中,显著较低水平标记假定癌症干细胞与错配修复缺陷状态相关。